{"id":8058,"date":"2024-08-26T08:14:00","date_gmt":"2024-08-26T08:14:00","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-secures-order-with-national-concierge-healthcare-organization-3\/"},"modified":"2024-11-18T19:04:32","modified_gmt":"2024-11-18T19:04:32","slug":"acarix-secures-order-with-national-concierge-healthcare-organization-3","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-secures-order-with-national-concierge-healthcare-organization-3\/","title":{"rendered":"Acarix Secures Order with National Concierge Healthcare Organization"},"content":{"rendered":"
\n

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces its first order of the CADScor System with a prominent U.S. concierge healthcare organization. This milestone aligns with the company’s strategic goal of expanding into new verticals, as detailed in the Q2 2024 Earnings Presentation.<\/strong><\/p>\n<\/div>\n

\n

The organization includes a network of over 1,000 physicians across the U.S., offering personalized primary care through a concierge model. It serves over 300,000 patients and emphasizes preventive medicine, providing enhanced access to doctors, comprehensive wellness programs, and 24\/7 availability. Their approach fosters closer doctor-patient relationships, focusing on proactive healthcare and improved outcomes.<\/p>\n

The adoption of the CADScor System is a testament to the organization’s commitment to providing innovative tools for early cardiac assessment. The CADScor System will support physicians in delivering personalized, preventive care to their symptomatic patients suspected of coronary artery disease.<\/p>\n

“We are thrilled to partner with a nationally recognized leader in personalized healthcare as we continue to drive our strategy of expanding into targeted verticals such as concierge medicine,” commented Aamir Mahmood, Acarix President and CEO. “This order represents a significant step forward in our mission to make rapid and accurate cardiac diagnostics at point of care accessible to more patients and physicians.”<\/p>\n

This achievement builds on the solid momentum reported in Acarix’s Q2 2024 earnings, where the company highlighted record patch sales and gross profit alongside a strategic focus on expanding into new healthcare segments. This partnership emphasizes Acarix’s commitment to growth and its ongoing efforts to transform early cardiac diagnostics.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com<\/a> <\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix Secures Order with National Concierge Healthcare Organization<\/a><\/p>\n<\/div>\n